Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials

Mease PJ, Gladman DD, Gomez-Reino JJ, Hall S, Kavanaugh A, Lespessailles E, Schett G, Paris M, Delev N, Teng L, Wollenhaupt J (2020)


Publication Type: Journal article

Publication year: 2020

Journal

Book Volume: 2

Pages Range: 459-470

Journal Issue: 8

DOI: 10.1002/acr2.11156

Abstract

ObjectivePsoriatic arthritis (PsA) requires long-term treatment, yet safety concerns and monitoring requirements make maintenance a challenge. This analysis of pooled Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE) 1, 2, and 3 data describes 3-year apremilast safety and tolerability in PsA.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Mease, P.J., Gladman, D.D., Gomez-Reino, J.J., Hall, S., Kavanaugh, A., Lespessailles, E.,... Wollenhaupt, J. (2020). Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials. ACR Open Rheumatology, 2(8), 459-470. https://doi.org/10.1002/acr2.11156

MLA:

Mease, Philip J., et al. "Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials." ACR Open Rheumatology 2.8 (2020): 459-470.

BibTeX: Download